Characteristics | SIB-IMRT group (n = 128) | Conventional IMRT group (n = 298) | P value |
---|---|---|---|
Age (years) | Â | Â | 0.934 |
 ≤ 70 | 110 (85.9%) | 257 (86.2%) |  |
 > 70 | 18 (14.1%) | 41 (13.8%) |  |
Gender | Â | Â | 0.76 |
 Male | 101 (78.9%) | 239 (80.2%) |  |
 Female | 27 (21.1%) | 59 (19.8%) |  |
KPS | Â | Â | 0.213 |
 ≥ 80 | 124 (96.9%) | 280 (94%) |  |
 < 80 | 4 (3.1%) | 18 (6%) |  |
Smoking | Â | Â | 0.214 |
 No | 37 (28.9%) | 68 (22.8%) |  |
 Yes | 91 (71.1%) | 230 (77.2%) |  |
PET staging | Â | Â | 0.486 |
 Yes | 47 (36.7%) | 99 (33.2%) |  |
 No | 81 (63.3%) | 199 (66.8%) |  |
Pathology | Â | Â | 0.251 |
 SCC | 74 (57.8%) | 190 (63.8%) |  |
 ADE | 47 (36.7%) | 86 (28.9%) |  |
 NSCLC | 7 (5.5%) | 22 (7.4%) |  |
TNM stage | Â | Â | 0.002* |
 IIIA | 39 (30.5%) | 140 (47%) |  |
 IIIB | 89 (69.5%) | 158 (53%) |  |
T stage | Â | Â | 0.009* |
 T1 | 11 (8.6%) | 10 (3.4%) |  |
 T2 | 50 (39.1%) | 86 (28.9%) |  |
 T3 | 31 (24.2%) | 100 (33.6%) |  |
 T4 | 36 (28.1%) | 102 (34.2%) |  |
N stage | Â | Â | 0.001* |
 N0 | 1 (0.8%) | 14 (4.7%) |  |
 N1 | 6 (4.7%) | 33 (11.1%) |  |
 N2 | 48 (37.5%) | 147 (49.3%) |  |
 N3 | 73 (57%) | 104 (34.9%) |  |
Treatment modality | Â | Â | 0.874 |
 RT alone | 11 (8.6%) | 28 (9.4%) |  |
 Sequential CRT | 59 (46.1%) | 141 (47.3%) |  |
 Concurrent CRT | 58 (45.3%) | 129 (43.3%) |  |
Prescribed dose (Gy) | Â | Â | 0.775 |
  ≥ 66 | 11 (8.6%) | 18 (6%) |  |
 59–66 | 98 (76.6%) | 237 (79.5%) |  |
 55–59 | 12 (9.4%) | 25 (8.4%) |  |
 50–55 | 7 (5.5%) | 18 (6%) |  |
PTV volume (ml) | 504 (128–960) | 402 (51–890) | < 0.001* |
PTV/lung volume ratio | 0.18 (0.04–0.43) | 0.12 (0.01–0.32) | < 0.001* |